Therapeutic pathway reprogramming for metabolic liver disease
Description: PROJECT NARRATIVE We recently pioneered a novel therapeutic concept for metabolic disease, metabolic pathway reprogramming, in which we reroute a metabolic pathway to a benign disease phenotype using genome editing tools. Using tyrosinemia type I as a model metabolic disorder, we will address the translational challenges of this genome editing approach in a murine disease model and human liver chimeric mice.
Funding type: research
Funder scheme: R56
Start date: 2017-09-13
End date: 2018-09-12
Investigator: KARL-DIMITER BISSIG
Institution: BAYLOR COLLEGE OF MEDICINE
Funded outputs count: 10
Funder award ID: R56DK115461
OpenAlex ID: G6631083644